INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
1. Pomerantz LLP is investigating claims of securities fraud against Edgewise Therapeutics. 2. Edgewise's stock fell 8.86% after FDA deemed trial data insufficient. 3. Investors can contact Pomerantz for class action information. 4. The investigation concerns misconduct by Edgewise officers and directors. 5. Positive trial results were overshadowed by FDA's disapproval of accelerated approval.